+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 16Years - 50Years
All Genders
ID04390646

Study of Pulsatile GnRH Therapy to Improve Thinking and Smell in Adolescents and Adults with Down Syndrome

Led by Nelly Pitteloud · Updated on 2024-02-12

56

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Down syndrome DS is the most common chromosomal disorder, with many adults living to age 65. Early Alzheimers disease AD is the leading cause of death in this group. Individuals with DS show AD-related brain changes by age 30 and develop clinical symptoms in their late 40s. They also experience problems with their sense of smell. Currently, no treatments address these cognitive or olfactory difficulties in DS. Researchers are studying a treatment using pulsatile gonadotropin-releasing hormone GnRH, a natural hormone involved in reproduction and brain functions. This study compares pulsatile GnRH therapy delivered through a subcutaneous pump with a placebo pump over 24 weeks. The treatment is given to people aged 16 to 50 with DS to assess effects on cognition and smell. Participants will undergo cognitive and behavioral assessments, blood tests for metabolic measures, and brain imaging. Researchers will measure changes in cognition from baseline to the end of treatment at week 24. Secondary tests include memory, language, and quality of life evaluations. Safety and health markers will also be monitored. The study includes random assignment to treatment or placebo and uses triple masking to ensure unbiased results.

CONDITIONS

Brief Title

GnRH Therapy on Cognition in Down Syndrome

Research Team

P

Pulse-UP study

T

Tommaso Todisco, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here